A hospital-acquired infection (HAI)is a new infection that develops in a patient during hospitalization. It is usually defined as an infection that is identified at least forty-eight to seventy-two hours following admission, so infections incubating, but not clinically apparent, at admission are excluded. This type of infection is also known as a nosocomial infection (or more generically healthcare-associated infections).
The industry has responded with a variety of testing and treatment products. This report, Hospital-Acquired Infections: Diagnostic Markets and Testing Developments, Treatments, Key Competitors and Trends presents the market opportunities for testing such infections and the role of treatment. The following market data is provided in this report:
Market for HAI Diagnostics
Forecast for HAI Diagnostics to 2015
HAI Tests on the Market
Market for Diagnostics by Infection Type (C. Diff., MRSA, Pneumonia, Other)
Molecular HAI Market vs. Conventional HAI Market, Present and in 2015
Geographic Breakdown of Testing (U.S., Europe, Asia, ROW)
New HAI Testing Products in the Market
HAI Treatment Products on the Market
HAI Antibiotic market Size and Forecast
This report primarily focuses on bacterial nosocomial infections with some mention of viral infections. The major consideration is given to bacterial nosocomial infections because a) they are the most frequent type of infections spread in the hospital setting, and b) the practical aspects of diagnosis and therapy are more meaningful based both on medical considerations and on market considerations.
Some of the issues discussed in this report include:
Development of Potential Life-Saving Products
Development of Fast Testing Systems
Growing Drug Resistance
Development of Better Pharmacodiagnostics
Market Opportunity and Growth Rates Expected in Diagnostics versus Treatment
Hospital Procedures for Use of Testing and Antibiotics
Attention to Special Population Issues
Demographics and Epidemiology
New Government Guidelines and Requirements for Preventing Infection
Focus on Alliances and Partnerships
Market analysis in this report focuses primarily on the epidemiological considerations and the size of patient groups both in the United States and globally, where available. We have accumulated the most recent data available, understanding that virtually no organization does extensive studies on these applications on a regular basis. Many studies are highly localized and may only apply to a community, state or country (more often countries that are not a part of the major markets for nosocomial diagnostic and therapeutic products). In many instances, we have had to draw from broader epidemiologic data, that is, on data that reach outside of the hospital environment in order to try and construct a picture of the nosocomial testing and treatment needs.
The primary focus of this report is on the bacterial form of nosocomial infections, and those with significant impact on the hospital setting and markets. In looking at these infections, we consider the diagnostic and therapeutic technologies that are currently available and attempt to project trends in these product areas. To some extent, we are limited by the activity of the industries associated with the diagnosis and treatment of these infections. For the most part, these activities are limited and the advanced technologies seen in other areas of medical application are not necessarily present in terms of microbiology.
The analysis presented in this report is based on data from a combination of company, government, industry, institutional and private sources. It includes information from extensive literature reviews and discussions with experts in the field, including microbiologists, pathologists, hospital authorities, research scientists, business development managers and marketing managers.
Companies profiled in this report are:
Bayer Schering Pharma
Johnson & Johnson
Merck & Co.
All Kalorama reports advertise the single user price, which limits access to one user. We also feature department and global pricing for reports that will be utilized by more than one user at your company. Please ask your sales representative or select the correct license on our website.
For Kalorama's take on the healthcare news of the week, based on our analysis of healthcare markets, follow Kalorama Information's Key Point Blog at http://kaloramakeypoint.blogspot.com/
New York, July 14, 2011-- When a Hospital-acquired infection (HAI) is suspected, hospitals need results quickly, which is good news for innovative diagnostic test makers, notes healthcare market research firm Kalorama Information. In its recent report, Hospital-Acquired Infections: Diagnostic Markets and Testing Developments, Treatments, Key Competitors and Trends, Kalorama predicts the combined world market for testing and treatment products for HAI will reach $10.3 billion in 2015, up from $9 billion in 2010, with higher growth experienced in the testing segment.
Kalorama's report finds nosocomial infections are an inherent part of any healthcare system and have a 5% infection rate of the 40 million hospital visits a year, causing 100,000 deaths in the U.S. annually. In an effort to decrease the rate of fatality, hospitals are shifting focus towards rapid discovery and treatment of nosocomial infections, driving sales of testing products.
"The growth opportunities are in testing," said Bruce Carlson, publisher of Kalorama Information. "The treatment market is slowing down, with a little growth in the future, which will be dominated by established pharmaceutical companies."
Specific nosocomial infections that are candidates for testing innovation, include Pneumonia, which comprises nearly 20% of all HAIs with 300,000 cases annually and has an associated mortality rate of 30-70%, as well as MRSA, which accounts for nearly 20,000 deaths a year. According to Kalorama, 20-30% of these infections are preventable through intensive hygiene and control programs and the remaining 70-80% through more involved measures, such as hospital architecture and air sanitation and the use of disposable equipment and supplies.
"Everyone is interested in faster tests and immediate results," added Carlson. "Although the rate of infection won't change, quicker turnover will improve patient outcome and drive down mortality rates."